◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Sawai Group Holdings Co., Ltd. (4887)

Name: Sawai Group Holdings Co., Ltd.（4887）— 财务报表历史
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

来自官方财务报表的收入、利润与现金流历史。

Healthcare · 华尔街（美国） · 最近更新： 2026-10-02

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the manufacture and sale of pharmaceuticals. The company offers generic drugs in various dosage forms for therapeutic areas comprising cardiovascular and antibiotic preparations, central nervous system drugs, other metabolic drugs, digestive tract medicines, blood and body fluid medications, allergy medications, respiratory medicine, vitamin supplements, oncology drugs, chemotherapeutic agents, genitourinary and anal drugs, and others. It sells its generic drugs through distributors, wholesalers, and retailers.

关键数据

市值: JPY 184 billion
收入（截至 2026-03-31 财年）: JPY 201.7B
净利润: JPY 10.4B
毛利率: 29.2%
净利率: 5.2%

查看交互式图表与完整报表 → 估值模型 (DCF) →

年度利润表

利润表	2026-03-31	2025-03-31	2024-03-31	2023-03-31
总收入	JPY 201.7B	JPY 189.0B	JPY 176.9B	JPY 163.7B
毛利	JPY 58.8B	JPY 56.4B	JPY 54.3B	JPY 50.3B
营业利润（EBIT）	JPY 15.9B	JPY 4.1B	JPY 18.6B	JPY 16.1B
净利	JPY 10.4B	JPY 12.0B	JPY 13.7B	JPY 12.7B

来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 4887 交互式查看器。 /companies/us/4887

类似公司

本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.